Objective  To investigate the clinical effect and safety of preoperative neoadjuvant chemotherapy combined with parenteral and enteral nutrition support in the treatment of pyloric obstruction of gastric cancer.

  Methods  The clinical data of 90 patients with pyloric obstruction of gastric cancer treated in our hospital in recent years were retrospectively analyzed, among whom 45 patients received preoperative neoadjuvant chemotherapy alone were selected as the reference group and 45 patients received preoperative neoadjuvant chemotherapy combined with parenteral as well as enteral nutrition were selected as the observation group. The nutritional status, short-term and long-term prognosis of the two groups were observed.

  Results  Before intervention, there were no significant differences between the two groups in the subjective total nutrition assessment (PG-SGA) score and the quality of life assessment scale (QOL) score (P>0.05). After intervention, the PG-SGA scores of the observation group was significantly lower, and the QOL score was significantly higher than that of the reference group(P < 0.05). The resection rate of tumor and radical resection rate were significantly higher, and the incidence of postoperative complications was significantly lower than that of the reference group (P < 0.05). The recurrence rate, metastasis rate and mortality rate within 3 years after operation of the observation group were significantly lower than those of the reference group (P < 0.05).

  Conclusion  Preoperative neoadjuvant chemotherapy combined with parenteral as well as enteral nutrition support in the treatment of pyloric obstruction of gastric cancer can improve the nutritional status of the body and the quality of life of patients. Meanwhile, it can improve the short-term and long-term effect of surgery, and reduce the risk of complications.